Lung Cancer Clinical Trials

Showing 2681-2700 of 4,288 trials

Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)

NCT04031898

Multinational, multi-center medical record review to describe the treatment patterns, clinical outcomes, and EGFR / T790M testing practices in EGFR-mutated advanced NSCLC patients receiving first-line EGFR TKI therapy in Europe.

Lung Cancer

AstraZeneca896 participantsStarted May 2019

Wien, Bulgaria

COMPLETEDPhase 1

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

NCT00456833

This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.

Non Small Cell Lung Cancer

Novartis Pharmaceuticals248 participantsStarted Jun 2005

Atlanta, Georgia, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +11 more locations

TERMINATEDPhase 3

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

NCT03516084

Niraparib is a PARP inhibitor. The study is a 2:1 randomized, double-blind, placebo-controlled, multi-center,phase 3 study of ZL-2306 (niraparib) as maintenance therapy following first-line platinum-based chemotherapy in patients with extensive-stage disease small cell lung cancer (ED-SCLC) to evaluate the efficacy and safety.

Extensive-stage Small Cell Lung Cancer

Zai Lab (Shanghai) Co., Ltd.185 participantsStarted Aug 2018

Hefei, Anhui, China • Beijing, Beijing Municipality, China • Beijing, Beijing Municipality, China +30 more locations

Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Related Searches

Safety of Everolimus and Pemetrexed in Lung Cancer Patients

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer

Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients

Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer

The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy

A Real-world Study of Durvalumab for Lung Cancer in China

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Vandetanib in Advanced NSCLC With RET Rearrangement

Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL)

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer

Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors